Pfizer Inc. and BioNTech SE have announced that the European Medicines Agency's $(EMA)$ Committee for Medicinal Products for Human Use $(CHMP)$ has recommended marketing authorization for their LP.8.1-adapted monovalent COVID-19 vaccine, COMIRNATY® LP.8.1, for active immunization in individuals aged 6 months and older. This recommendation is based on evidence supporting the safety and efficacy of the vaccine, which targets the LP.8.1 variant to maintain vaccine effectiveness as SARS-CoV-2 continues to evolve. The European Commission is expected to make a final decision soon. Pfizer and BioNTech have already started manufacturing the vaccine to ensure readiness for the upcoming fall and winter season.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250724404161) on July 25, 2025, and is solely responsible for the information contained therein.